Mammary Cell News Volume 13.41 | Nov 4 2021

    0
    55







    2021-11-04 | MCN 13.41


    Mammary Cell News by STEMCELL Technologies
    Vol. 13.41 – 4 November, 2021
    TOP STORY

    Fasting-Mimicking Diet Blocks Triple-Negative Breast Cancer and Cancer Stem Cell Escape

    The authors reported that a fasting-mimicking diet activated starvation escape pathways in TNBC cells, which could be identified and targeted by drugs. They found that metastatic TNBC patients with lower glycemia survived longer than those with higher baseline glycemia.
    [Cell Metabolism]

    Full ArticleGraphical Abstract

    Dr. Kristina McBurney and Leanna Bedell discuss how you can use social media to advance your scientific career. Watch now.
    PUBLICATIONSRanked by the impact factor of the journal

    Differential Phase Register of Hes1 Oscillations with Mitoses Underlies Cell-Cycle Heterogeneity in ER+ Breast Cancer Cells

    Scientists studied the dynamical expression of endogenously labeled Hes1, a transcriptional repressor implicated in controlling cell proliferation, to understand how cell-cycle length heterogeneity was generated in estrogen receptor (ER)+ breast cancer cells.
    [Proceedings of the National Academy of Sciences of the United States of America]

    Full Article

    HIF-1–Regulated Expression of Calreticulin Promotes Breast Tumorigenesis and Progression through Wnt/β-Catenin Pathway Activation

    Researchers demonstrated that calreticulin facilitated breast cancer progression by promoting the breast cancer stem cell phenotype through Wnt/β-catenin signaling in a hypoxia-inducible factor 1 (HIF-1)–dependent manner.
    [Proceedings of the National Academy of Sciences of the United States of America]

    Abstract

    CRISPR Interference and Activation of the microRNA-3662-HBP1 Axis Control Progression of Triple-Negative Breast Cancer

    Investigators found that inhibition or knockout of endogenous, mature microRNA-3662 in TNBC cells suppressed proliferation and migration in vitro and tumor growth and metastasis in vivo.
    [Oncogene]

    Abstract

    ARSD, a Novel ERα Downstream Target Gene, Inhibits Proliferation and Migration of Breast Cancer Cells via Activating Hippo/YAP Pathway

    Researchers found a set of hormone-responsive lineage-specific transcription factors, FOXA1, GATA3, ERα, directly drove high expression of arylsulfatase D (ARSD) through chromatin looping in luminal subtype breast cancer cells.
    [Cell Death & Disease]

    Full Article

    TCOF1 Upregulation in Triple-Negative Breast Cancer Promotes Stemness and Tumor Growth and Correlates with Poor Prognosis

    Researchers demonstrated that KIT was a downstream effector of TCOF1 in mediating TNBC stemness, evaluated by in vitro and in vivo assays.
    [British Journal of Cancer]

    Full Article

    LIFR Inhibition Enhances the Therapeutic Efficacy of HDAC Inhibitors in Triple Negative Breast Cancer

    Investigators showed that first-in-class leukemia inhibitory factor receptor (LIFRα) inhibitor EC359 could enhance the therapeutic efficacy of histone deacetylase inhibitors (HDACi) against TNBC.
    [Communications Biology]

    Full Article

    FBXL10 Promotes EMT and Metastasis of Breast Cancer Cells via Regulating the Acetylation and Transcriptional Activity of SNAI1

    Researchers revealed that F-box and leucine-rich repeat protein 10 (FBXL10) served as a pro-metastatic factor in breast cancer via repressing the expression of E-cadherin and inducing epithelial-mesenchymal transition (EMT).
    [Cell Death Discovery]

    Full Article

    Co-Delivery of Doxorubicin and Conferone by Novel pH-Responsive β-Cyclodextrin Grafted Micelles Triggers Apoptosis of Metastatic Human Breast Cancer Cells

    Researchers showed that combination delivery of Doxorubicin (Dox) and Conferone (Conf) to MDA-MB-231 human breast cancer cells had synergistic effects, where Dox-Conf loaded micelles significantly induced tumor cell apoptosis.
    [Scientific Reports]

    Full Article

    Metabolic Profiling of Attached and Detached Metformin and 2-Deoxy-D-Glucose Treated Breast Cancer Cells Reveals Adaptive Changes in Metabolome of Detached Cells

    Scientists performed LC/MS metabolic profiling on separated attached and detached MDA-MB-231 cells treated with metformin and/or 2-deoxy-D-glucose and found that the metabolic profile of detached cells was closer to untreated control cells, suggesting detachment might help cells adapt to energy stress.
    [Scientific Reports]

    Full Article
    Stay up-to-date with the latest stem cell research by listening to the Stem Cell Podcast!
    REVIEWS

    The Role of Membrane Mucin MUC4 in Breast Cancer Metastasis

    Investigators discuss the diverse roles of MUC4 in tumor progression and metastasis, and propose that intervening in MUC4 intercellular interactions with binding partners on blood-borne aggregating cells could potentially thwart breast cancer metastatic efficiency.
    [Endocrine-Related Cancer]

    Abstract

    PERK, Beyond an Unfolded Protein Response Sensor in Estrogen-Induced Apoptosis in Endocrine-Resistant Breast Cancer

    Scientists address the mechanistic progress on how PRK-like endoplasmic reticulum kinase (PERK) acts as a multifunctional molecule to commit 17β-estradiol to inducing apoptosis in endocrine-resistant breast cancer.
    [Molecular Cancer Research]

    Abstract

    Breast Cancer Immune Microenvironment: From Pre-Clinical Models to Clinical Therapies

    The authors examine the role of immune-activating cells, including tumour-infiltrating lymphocytes, and natural killer cells, as well as immune inhibitory cells, including T regulatory cells, and myeloid-derived suppressor cells in the breast cancer tumour microenvironment.
    [Breast Cancer Research and Treatment]

    Abstract
    INDUSTRY AND POLICY NEWS

    Ambrx Biopharma Inc. Announces First Patient Dosed in its Global Phase II ACE-Breast-03 Clinical Study of ARX788 for the Treatment of HER2-Positive Metastatic Breast Cancer

    Ambrx Biopharma, Inc. announced the first patient has been dosed in its global ACE-Breast-03 Phase II clinical study of ARX788, an anti-HER2 antibody drug conjugate, in patients with HER2-positive metastatic breast cancer.
    [Ambrx Biopharma, Inc.]

    Press Release
    FEATURED EVENT

    American College of Toxicology Annual Meeting

    November 10 – 19, 2021
    Virtual

    > See All Events

    JOB OPPORTUNITIES

    Faculty Position – Hormone-Related Cancers

    University of Maryland School of Medicine – Baltimore, Maryland, United States

    Postdoctoral Fellow – Cancer Biology

    Georgetown University School of Medicine – Washington, District of Columbia, United States

    Postdoctoral Position – Translational Oncology

    Medical University of Vienna – Vienna, Austria

    Postdoctoral Fellow – Tumor Heterogeneity and Development of Resistant Cancer

    City of Hope – Los Angeles, California, United States

    Postdoctoral Fellow – Molecular and Cellular Oncology

    The University of Texas MD Anderson Cancer Center – Houston, Texas, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Mammary Cell News Twitter